Novel PRRT2 mutation in an African-American family with paroxysmal kinesigenic dyskinesia by Peter Hedera et al.
Hedera et al. BMC Neurology 2012, 12:93
http://www.biomedcentral.com/1471-2377/12/93RESEARCH ARTICLE Open AccessNovel PRRT2 mutation in an African-American
family with paroxysmal kinesigenic dyskinesia
Peter Hedera1†, Jianfeng Xiao2†, Andreas Puschmann3, Dragana Momčilović4, Steve W Wu5 and Mark S LeDoux2*Abstract
Background: Recently, heterozygous mutations in PRRT2 (Chr 16p11.2) have been identified in Han Chinese,
Japanese and Caucasians with paroxysmal kinesigenic dyskinesia. In previous work, a paroxysmal kinesigenic
dyskinesia locus was mapped to Chr 16p11.2 - q11.2 in a multiplex African-American family.
Methods: Sanger sequencing was used to analyze all four PRRT2 exons for sequence variants in 13 probands
(9 Caucasian, 1 Caucasian-Thai, 1 Vietnamese and 2 African-American) with some form of paroxysmal dyskinesia.
Results: One patient of mixed Caucasian-Thai background and one African-American family harbored the
previously described hotspot mutation in PRRT2 (c.649dupC, p.R217Pfs*8). Another African-American family was
found to have a novel mutation (c.776dupG, p.E260*). Both of these variants are likely to cause loss-of-function via
nonsense-mediated decay of mutant PRRT2 transcripts. All affected individuals had classic paroxysmal kinesigenic
dyskinesia phenotypes.
Conclusions: Heterozygous PRRT2 gene mutations also cause paroxysmal kinesigenic dyskinesia in
African-Americans. The c.649dupC hotspot mutation in PRRT2 is common across racial groups.
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Paroxysmal kinesigenic dyskinesia (PKD, OMIM 128000),
also known as episodic kinesigenic dyskinesia (EKD1) and
paroxysmal kinesigenic choreoathetosis (PKC), is a rare
autosomal dominant neurological disorder characterized
by recurrent, brief attacks of involuntary movement usu-
ally triggered by sudden voluntary movement [1,2].
These attacks usually begin in childhood or early adult-
hood and may include various combinations of dystonia,
chorea, and athetosis affecting the face, trunk, arms and
legs. Oftentimes, PKD improves with age and most
patients show a favorable response to anticonvulsant
medications, particularly carbamazepine or phenytoin
[1,2]. Recently, mutations in PRRT2 (Chr 16p11.2) have
been causally associated with both familial and sporadic
cases of PKD, infantile convulsions and choreoathetosis* Correspondence: mledoux@uthsc.edu
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reproduction in any medium, provided the orexercise-induced dyskinesia (PED), and paroxysmal non-
kinesigenic dyskinesia-like (PNKD-like) syndromes in
Han Chinese, Japanese and Caucasians [3-11].
PKD is clinically and genetically heterogeneous, and, in
at least one British pedigree, does not map to Chr 16 [12].
Work to date suggests that fewer than 50% of patients
with primary PKD harbor mutations in PRRT2 [6,8]. To
expand the genotypic spectrum of PRRT2 mutations and
examine the role of PRRT2 in other racial groups, we re-
port the clinical and genetic data for 13 probands with
paroxysmal dyskinesias including 1 Vietnamese, 1 mixed
Caucasian-Thai and 2 African-Americans.Methods
All human studies were performed in accordance with
institutional review board guidelines at each participat-
ing institution, the Helsinki Declaration, and written
informed consent for genetic studies and publication of
clinical data was obtained from all subjects or, where
participants were children, their parents. All genetic and
phenotypic analyses and publication of the results were
approved by the University of Tennessee Health ScienceLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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jects were acquired from outpatient clinics at participat-
ing institutions. Clinical diagnoses were made by means
of history and examination by one or more board-
certified neurologists at each institution. Clinical and
genetic details for 13 probands are presented Table 1.
DNA was extracted from peripheral blood leucocytes
using Roche’s DNA Isolation Kit for Mammalian Blood
(Indianapolis, IN, USA). DNA quantity and quality were
analyzed with a NanoDrop ND-1000 spectrophotometer
(Wilmington, DE, USA) and agarose gel electrophoresis.
With Primer3 (frodo.wi.mit.edu), four pairs of PCR pri-
mers were designed to encompass the four PRRT2 exons
and flanking intronic regions (Additional file 1 Table
S1). For Sanger sequencing, PCR was performed using
50 ng of template DNA, 1X PCR buffer, 2.5 mM MgCl2
and 200 nM of each primer in a 20-μl reaction volume.
The following cycling conditions were employed: 95°C
for 15 min; 35 cycles at 95°C for 15 s, 60°C for 15 s, and
72°C for 45 s; and 72°C for 10 min. After agarose gel
confirmation, 5 μl of the PCR products were cleaned
using ExoSAP-ITW (United States Biochemical, Cleve-
land, OH, USA). Then, 1-2 μl of the purified PCR pro-
ducts were sequenced in the forward and reverse
directions on the Applied Biosystems 3130XL Genetic
Analyzer (Carlsbad, CA, USA). Control DNA samples
(100 African-American and 100 Caucasian) were
sequenced for detection of newly-identified PRRT2
mutations.
Results
Among 13 index cases with paroxysmal dyskinesias, two
different mutations in three families were identified. A
novel mutation was found in African-American Family
A (Figure 1, c.776dupG, p.E260*). This mutation was not
found in 100 African-American or 100 Caucasian nor-
mal controls. The proband was a 22-year-old female
(Figure 1, III-3), who noticed the first attack of chorei-
form and dystonic movements in her hands and arms at
age 12. Subsequent episodes also included dystonia in
her legs and face. Her father and all three sisters have
similar clinical features during attacks with dystonia in
the face, arms and legs, along with chorea in the hands.
Although DNA specimens were not available from her
father and two older sisters, the c.776dupG mutation
was confirmed in her youngest sister (III-4). All affected
family members responded to either carbamazepine or
phenytoin. Two of the three family members currently
taking phenytoin did not tolerate carbamazepine due to
sedative effects.
The previously reported hotspot mutation (c.649dupC,
p.R217Pfs*8) was found in African-American Family B
(Figure 1) and an individual of mixed Caucasian-Thai
background. The c.649dupC variant was not found in100 African-American or 100 Caucasian normal con-
trols. Case 7 had late-onset (>20 y) but otherwise classic
carbamazepine-responsive PKD. Prior to initiation of
therapy with carbamazepine, sudden movements were
more likely to precipitate dystonic posturing when the
patient was under psychological stress. Attacks often
consisted of dystonic posturing of the left arm in abduc-
tion along with cervical dystonia. Occasionally, similar
attacks affected the right side of the body. Although his
Thai mother had no history of PKD, ICCA or BFIE and
was found to be neurologically normal, Sanger sequen-
cing revealed that she was a carrier, and several of her
family members reportedly had infantile seizures.
No sequence variants were identified in the remaining
10 probands (9 Caucasian, 1 Vietnamese) with PED,
ICCA, PKD or PNKD, 3 of whom had a positive family
history. All but two of these individuals had early-onset
(< 20 y) paroxysmal dyskinesias. Age of onset, attack fre-
quency and attack duration were much more variable
among the mutation-negative cases in comparison to the
patients with PRRT2 mutations.
Discussion
Candidate regions for PKD and ICCA were mapped to
Chr 16 over a decade ago. PKD was linked to a 15.8 cM
region flanked by markers D16S685 and D16S503 on
Chr 16q13-q22.1 with a maximum LOD score of 3.66 at
D16S419 in a large Indian family [13]. This candidate re-
gion was telomeric to a locus identified in Japanese fam-
ilies with PKD [14], but showed overlap with a region
identified in an African-American family with PKD [15].
A candidate region for ICCA had also been mapped to
the pericentromeric region of Chr 16 in French [16] and
Chinese [17] families.
Just recently, several distinct loss-of-function frameshift
mutations leading to protein truncation or nonsense-
mediated decay in proline-rich transmembrane protein 2
(PRRT2) have been associated with PKD in numerous
Han Chinese families [3-6]. A much smaller percentage
of cases were associated with missense mutations (e.g.,
c.796C>T, p.R266W; c.913 G>A, p.G305R) [4,6]. In
addition to classic carbamazepine-responsive PKD, the
phenotypic spectrum of PRRT2 mutations includes cases
of ICCA, BFIE, some “PNKD-like” syndromes, and PED
[6-11]. PRRT2 is located on Chr 16p11.2, within the
ICCA, Japanese PKD, and African-American candidate
regions but outside the Indian PKD candidate region.
The association of PRRT2 genotypes with specific neuro-
logical phenotypes may become apparent with the publi-
cation of additional well-characterized cases.
PRRT2 is a cell surface protein containing two pre-
dicted transmembrane domains and highly expressed in
the developing nervous system, particularly the cerebel-
lum [3]. Our study has shown that novel and hotspot
Table 1 Clinical details and genetic results for subjects with paroxysmal dyskinesias
Subject (Diagnosis) PRRT2
Mutation














Family A, II-1 (PKD) NA NA/M African-American 10y Yes < 100/day 10-20 sec SM D, C A, L carbamazepine(+),
phenytoin (+)
Family A, III-1 (PKD) NA 28y/F African-American 12y Yes 20-30/day 10-40 sec SM D, C F, A, L phenytoin (+)
Family A, III-2 (PKD) NA 25y/F African-American 10y Yes 50-75/day 10-15 sec SM D, C A, L carbamazepine (+)
Family A, III-3 (PKD) c.776dupG 22y/F African-American 10y Yes 30-40/day 10-15 sec SM D, C F, A, L carbamazepine(+),
phenytoin(+)
Family A, III-4 (PKD) c.776dupG 18y/F African-American 13y Yes 20-30/day 10-60 sec SM D, C F, A, L carbamazepine(+)
Family B (PKD) c.649dupC 30y/M African-American 12y Yes 50/day 10-60 sec SM D, C F, A phenytoin (+)
Case 7 (PKD) c.649dupC 27y/M Caucasian-Thai 21y *Yes 3-6/day < 10 sec SM, S D F, A, L carbamazepine (+)
Case 8 (PED) None 29y/F Caucasian < 28y No < 1/day 2-4 hrs Intense exercise D F, A, L clonazepam (±)
Case 9 (PKD) None 18y/M Caucasian 14y No 5-8/day < 15 sec SM D F, A, L carbamazepine (+)
Case 10 (ICCA) None 19mo/M Caucasian 7 m No >100/day 40-50 sec SM D, C, A F, A, L carbamazepine (+)
Case 11 (PKD) None 41y/F Caucasian < 33y Yes 20-25/mo 2-30 min SM, S D F, A, L piracetam (±)
clonazepam (±)
Case 12 (PKD) None 20y/M Caucasian 3y No 6-7/day 5-60 sec SM, S D, C, A F, A, L carbamazepine (+)
Case 13 (PKD) None 18y/M Caucasian 15y Yes 2-5/day 5-6 sec SM D F, A, L carbamazepine (+)
Case 14 (PKD) None 18y/F Caucasian 15y No 3-4/day < 10 sec SM, S D, C, A F, A, L carbamazepine (+)
Case 15 (PKD) None 14y/M Vietnamese 12y No 10/day 15-60 sec S D A, L acetazolamide (+)
Case 16 (PKD) None 26y/F Caucasian 16y No 30/day 20-30 sec SM D A phenytoin (+)
Case 17 (PNKD) None 6y/F Caucasian 6 m Yes 2-10/mo 3-60 min Fatigue,
sleep deprivation
D A, L NA
Involuntary movements: D-dystonia, C-chorea, and A-athetosis. Anatomical distribution: F-face, A-arm, and L-leg.
Triggers: SM-sudden movement and S-stress. NA, DNA or clinical detail not available. Response to anticonvulsants:



















Figure 1 African-American PKD pedigrees. Males are represented by squares, females by circles. Affected individuals are represented by filled/
black symbols and asymptomatic family members by empty/white symbols. Symbols of deceased individuals are slashed. Probands are denoted
with arrows.
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African-Americans. The c.776dupG and c.649dupC
mutations are heterozygous SNindels (single nucleotide
insertions or deletions) predicted to cause nonsense-
mediated decay of mutant transcripts rather than ex-
pression of a truncated protein [18,19]. SNindels occur
at an estimated frequency of 0.887 per 10 kb of genomic
DNA with more than half occurring in regions with
mononucleotide repeats [19]. The novel c.776dupG mu-
tation is located within a 6 nucleotide (nt) poly-G tract
and the c.649dupC hot spot mutation is in a 9 nt poly-C
tract. SNindels within regions of mononucleotide repeats
may arise from replication slippage [19].Conclusions
The novel c.776dupG mutation and c.649dupC hot spot
mutation identified in our African-American families
with classic PKD expands the molecular and racial spec-
trums of PRRT2 mutations. As evidenced from our pa-
tient of mixed Caucasian-Thai descent, the penetrance
of PRRT2 mutations may depend on the origin of the
normal or wild-type allele. Finally, a significant percent-
age of patients with PKD and ICCA do not harbor
mutations in coding regions of PRRT2.Additional file
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